Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SYNLOGIC, INC. has filed a new activist 13D, reporting 32.9% ownership in $MIRN - https://fintel.io/so/us/mirn
Yes, higher highs and higher lows, hopefully it will close higher tomorrow.
* * $MIRN Video Chart 11-21-16 * *
Link to Video - click here to watch the technical chart video
$MIRN Technical Analysis
http://www.barchart.com/technicals/stocks/MIRN
Yep...when it wasn't bouncing back I sold at 2.44 about a week ago...
luckily
It's official, you were indeed missing something.
$72 million cash..no debt..20 million share out..
Should b $3/share unless I'm missing more info..
Seen the latest trials weren't good..death..but..
I like the RISK here.. Waiting to add..
Good luck
Big drop...found no news..took a RISK @ $2.49 ..
Good luck..
Good, I missed the time it ran to $11... :)
Is the chart looking good?
Annual Report...
http://ih.advfn.com/p.php?pid=nmona&article=70930774&symbol=MIRN
I will try to be there if possible
I plan to attend...
Mirna Therapeutics to Host Conference Call and Webcast of Fourth Quarter and Full Year 2015 Financial Results on March 29, 2016
http://ih.advfn.com/p.php?pid=nmona&article=70853505&symbol=MIRN
Me too and Dr Von Hoff is on the Advisor Board. That's what I hold it for long term
Go $MIRN
With a lot of upside potential. Did you see it hit $11? I never time things right... :). But I like this one...
Yes and I think it is another long term investment for us
You holding? I am a little bit... :)
What's going on here?
Another look.
https://www.tradingview.com/x/Vu6pEe8o/
Mirna Therapeutics C (MIRN)
6.11 ? 0.02 (0.33%)
Volume: 25,568 @ 8:54:10 PM ET
Bid Ask Day's Range
5.55 6.29 5.55 - 6.13
MIRN Detailed Quote Wiki
Mirna Therapeutics Announces Presentation of Interim Data from Ongoing Phase I Clinical Trial of MRX34, First-in-Class microR...
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the presentation of interim results from its ongoing Phase 1 clinical trial of MRX34, the Company’s lead therapeutic product candidate.1 The poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, reported interim Phase 1 clinical results for MRX34 from 75 patients with advanced solid tumors. MRX34 is a double-stranded “mimic” of the naturally occurring tumor suppressor microRNA (miRNA) miR-34, encapsulated in the SMARTICLES® liposomal delivery formulation.
Interim safety, efficacy and biomarker data from the multicenter, open-label Phase 1 clinical trial in solid tumor patients show that MRX34 has a safety profile manageable with standard interventions or tests used by oncologists, and demonstrate the therapeutic potential of miR-34 replacement therapy. Additionally, dose-dependent effects on miR-34 target genes in patients’ white blood cells have been observed. As of August 13, 2015, two patients with advanced, metastatic Stage IV cancer have achieved clinical responses after treatment with MRX34: one patient with primary liver cancer (hepatocellular carcinoma, HCC) metastatic to the lung, and one patient with acral melanoma, metastatic to lymph nodes, showed more than 30 percent tumor shrinkage (confirmed partial responses).
The findings were presented on Sunday, November 8, in a poster presentation entitled “Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors” by primary author Muhammad Shaalan Beg, M.D., Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center.
“These results further confirm our excitement about the MRX34 program, demonstrating early, promising therapeutic potential of microRNA replacement therapy in patients with advanced Stage IV cancer,” commented Paul Lammers, M.D., President and Chief Executive Officer of Mirna. “We look forward to the expansion phase of this trial in which we expect to enroll more patients with these as well as other cancer types.”
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced the presentation of interim results from its ongoing Phase 1 clinical trial of MRX34, the Company’s lead therapeutic product candidate.1 The poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, reported interim Phase 1 clinical results for MRX34 from 75 patients with advanced solid tumors. MRX34 is a double-stranded “mimic” of the naturally occurring tumor suppressor microRNA (miRNA) miR-34, encapsulated in the SMARTICLES® liposomal delivery formulation.
Interim safety, efficacy and biomarker data from the multicenter, open-label Phase 1 clinical trial in solid tumor patients show that MRX34 has a safety profile manageable with standard interventions or tests used by oncologists, and demonstrate the therapeutic potential of miR-34 replacement therapy. Additionally, dose-dependent effects on miR-34 target genes in patients’ white blood cells have been observed. As of August 13, 2015, two patients with advanced, metastatic Stage IV cancer have achieved clinical responses after treatment with MRX34: one patient with primary liver cancer (hepatocellular carcinoma, HCC) metastatic to the lung, and one patient with acral melanoma, metastatic to lymph nodes, showed more than 30 percent tumor shrinkage (confirmed partial responses).
The findings were presented on Sunday, November 8, in a poster presentation entitled “Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors” by primary author Muhammad Shaalan Beg, M.D., Assistant Professor, Internal Medicine, University of Texas Southwestern Medical Center.
“These results further confirm our excitement about the MRX34 program, demonstrating early, promising therapeutic potential of microRNA replacement therapy in patients with advanced Stage IV cancer,” commented Paul Lammers, M.D., President and Chief Executive Officer of Mirna. “We look forward to the expansion phase of this trial in which we expect to enroll more patients with these as well as other cancer types.”
you are very welcome. MIRN
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, announced the appointment of Dr. Miguel Barbosa, Ph.D. as Executive Vice President and Chief Scientific Officer.
Dr. Barbosa has joined the Company with 20 years of biopharmaceutical research discovery experience. For the past decade, he served in senior leadership roles at several Johnson & Johnson subsidiaries. Most recently, Dr. Barbosa was Executive in Residence, Therapeutic Innovation at Johnson & Johnson Innovation, where he led the identification and development of new R&D and business models. Prior to that, he was Vice President, Immunology Research & External Innovation, at Janssen Research & Development L.L.C., also a J&J company, where he led immunology discovery and translational research programs. Earlier in his career, he served as Vice President, Discovery Research, at J&J’s Centocor Research & Development, Inc.
“We are pleased to welcome Miguel to the role of Chief Scientific Officer,” said Paul Lammers, M.D., M.Sc., Mirna's President and Chief Executive Officer. “As a highly accomplished industry executive with a proven ability to lead top research and development programs, we are confident Miguel’s expertise and strategic vision, particularly in emerging areas of science, will prove critical as we advance our pipeline of microRNA-based oncology therapeutics.”
Dr. Barbosa received a B.S. in Genetics from the University of California, Davis, and a Ph.D. in Microbiology & Immunology from the University of California, Los Angeles, and completed his training at the National Cancer Institute.
How about a chart for today? Thanks
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
84
|
Created
|
10/20/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |